Vlidaplit M Tablet is a fixed-dose combination of two well-established antidiabetic agents—Metformin and Vildagliptin—used for the effective management of type 2 diabetes mellitus. This formulation is designed to help improve blood glucose control in adult patients who are unable to achieve sufficient glycemic control through diet and exercise alone or with monotherapy.
Metformin is a biguanide class medication that works primarily by reducing hepatic glucose production, enhancing peripheral insulin sensitivity, and improving glucose uptake by muscles. It is one of the most widely prescribed first-line treatments for type 2 diabetes due to its proven efficacy and safety profile.
Vildagliptin belongs to the DPP-4 (Dipeptidyl Peptidase-4) inhibitor class and functions by increasing the levels of incretin hormones. This enhances the secretion of insulin and suppresses the release of glucagon in a glucose-dependent manner, helping regulate postprandial and fasting blood sugar levels.
Together, the combination of Vildagliptin and Metformin offers a synergistic mechanism of action that improves overall glycemic control with a lower risk of hypoglycemia. The dual therapy targets multiple pathophysiological defects of type 2 diabetes, including insulin resistance, impaired insulin secretion, and excessive hepatic glucose output.
Vlidaplit M is typically prescribed as part of a comprehensive treatment plan that includes diet, exercise, and weight control. It helps in minimizing fluctuations in blood sugar, potentially reducing the risk of long-term diabetic complications such as nephropathy, neuropathy, and cardiovascular issues.
This formulation is especially suitable for patients requiring escalation from monotherapy or those who show inadequate response to either Vildagliptin or Metformin alone. Additionally, it is well tolerated and does not usually lead to significant weight gain.
By improving insulin sensitivity and glycemic control, Vlidaplit M not only manages blood glucose effectively but also contributes to the overall metabolic well-being of diabetic individuals.